CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On January 22, 2019, Caladrius Biosciences, Inc. (the “Company”) posted a letter to its shareholders on its website in connection with the Company’s recent accomplishments, goals and objectives for the calendar year 2019 and beyond. In addition, a copy of this letter is being mailed to shareholders. A copy of this letter is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.
The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, except as otherwise expressly stated in such filing.
Item 9.01. Financial Statement and Exhibits.
Shareholder Letter, dated January 22, 2019
CALADRIUS BIOSCIENCES, INC. Exhibit
EX-99.1 2 exhibit99shdrltr.htm EXHIBIT 99.1 exhibit99shdrltr Exhibit 99.1 January 22,…
To view the full exhibit click
About CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS)
Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company’s T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases.